
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7670135/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Correlation between a quantitative antiâ€SARSâ€CoVâ€2 IgG ELISA and neutralization activity. Journal of Medical Virology, 2022, 94, 388-392.	5.0	89
2	Recessive NLRC4-Autoinflammatory Disease Reveals an Ulcerative Colitis Locus. Journal of Clinical Immunology, 2022, 42, 325-335.	3.8	17
3	RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection. Molecular Therapy - Nucleic Acids, 2022, 27, 1225-1234.	5.1	14
4	Deficiency in coatomer complex I causes aberrant activation of STING signalling. Nature Communications, 2022, 13, 2321.	12.8	43
5	Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity. , 2022, 10, e003863.		3
6	Human Beta Papillomavirus Type 8 E1 and E2 Proteins Suppress the Activation of the RIG-I-Like Receptor MDA5. Viruses, 2022, 14, 1361.	3.3	6
7	Expression of a Functional Mx1 Protein Is Essential for the Ability of RIG-I Agonist Prophylaxis to Provide Potent and Long-Lasting Protection in a Mouse Model of Influenza A Virus Infection. Viruses, 2022, 14, 1547.	3.3	1
8	Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections. Transfusion Medicine and Hemotherapy, 2021, 48, 154-160.	1.6	4
9	Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ TÂcell help. Cell Reports, 2021, 35, 109320.	6.4	47
10	Monocyte-dependent co-stimulation of cytokine induction in human γδT cells by TLR8 RNA ligands. Scientific Reports, 2021, 11, 15231.	3.3	5
11	Extracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications. International Journal of Molecular Sciences, 2021, 22, 9211.	4.1	13
12	Malaria parasites both repress host CXCL10 and use it as a cue for growth acceleration. Nature Communications, 2021, 12, 4851.	12.8	22
13	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nature Communications, 2021, 12, 5505.	12.8	30
14	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. , 2021, 228, 107931.		18
15	Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy. Nature Communications, 2021, 12, 6530.	12.8	16
16	BIOM-24. PROTEIN SURFACE SIGNATURE ON SERUM EXTRACELLULAR VESICLES FOR NON-INVASIVE DETECTION OF TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2021, 23, vi15-vi16.	1.2	0
17	High RICâ€I expression in ovarian cancer associates with an immuneâ€escape signature and poor clinical outcome. International Journal of Cancer, 2020, 146, 2007-2018.	5.1	38
18	Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. International Journal of Molecular Sciences, 2020, 21, 7211.	4.1	17

GUNTHER HARTMANN

#	Article	IF	CITATIONS
19	Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids. Immunity, 2020, 53, 54-77.	14.3	115
20	Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nature Communications, 2020, 11, 5829.	12.8	207
21	Absence of cGAS-mediated type I IFN responses in HIV-1–infected T cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19475-19486.	7.1	20
22	A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. Tumor Biology, 2020, 42, 101042832095860.	1.8	3
23	U-DCS: characterization of the first permanent human dendritic sarcoma cell line. Scientific Reports, 2020, 10, 21221.	3.3	2
24	The coffee ingredients caffeic acid and caffeic acid phenylethyl ester protect against irinotecanâ€induced leukopenia and oxidative stress response. British Journal of Pharmacology, 2020, 177, 4193-4208.	5.4	11
25	Immune Sensing of Synthetic, Bacterial, and Protozoan RNA by Toll-like Receptor 8 Requires Coordinated Processing by RNase T2 and RNase 2. Immunity, 2020, 52, 591-605.e6.	14.3	83
26	Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. Journal of Clinical Investigation, 2020, 130, 4266-4281.	8.2	27
27	BIOM-40. ANALYSIS OF SERUM MIRNA IN GLIOBLASTOMA PATIENTS: TARGETED ENRICHMENT OF EXTRACELLULAR VESICLES ENHANCES SPECIFICITY FOR PROGNOSTIC SIGNATURE. Neuro-Oncology, 2020, 22, ii10-ii10.	1.2	0
28	The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu. Journal of Molecular Medicine, 2019, 97, 1589-1600.	3.9	7
29	Human TLR8 Senses RNA From Plasmodium falciparum-Infected Red Blood Cells Which Is Uniquely Required for the IFN-Î ³ Response in NK Cells. Frontiers in Immunology, 2019, 10, 371.	4.8	26
30	Targeted Nanoparticle Delivery of Bifunctional RIG-I Agonists to Pancreatic Cancer. Molecular Therapy, 2019, 27, 491-492.	8.2	7
31	Interferon-beta-induced changes in neuroimaging phenotypes of appetitive motivation and reactivity to emotional salience. NeuroImage: Clinical, 2019, 24, 102020.	2.7	3
32	Direct RIGâ€I activation in human NK cells induces TRAILâ€dependent cytotoxicity toward autologous melanoma cells. International Journal of Cancer, 2019, 144, 1645-1656.	5.1	23
33	Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms. Frontiers in Pharmacology, 2019, 10, 1620.	3.5	3
34	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clinical Cancer Research, 2018, 24, 1337-1343.	7.0	71
35	Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA. Oncotarget, 2018, 9, 22523-22536.	1.8	40
36	ATG16L1 orchestrates interleukin-22 signaling in the intestinal epithelium via cGAS–STING. Journal of Experimental Medicine, 2018, 215, 2868-2886.	8.5	122

#	Article	IF	CITATIONS
37	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncolmmunology, 2017, 6, e1320626.	4.6	89
38	RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation. Cancer Immunology Research, 2017, 5, 455-467.	3.4	29
39	Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer. Tumor Biology, 2017, 39, 101042831771138.	1.8	9
40	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. Clinical Chemistry, 2017, 63, 1288-1296.	3.2	97
41	Nucleic Acid Immunity. Advances in Immunology, 2017, 133, 121-169.	2.2	205
42	Clinical performance of LOCIâ,,¢-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers. Tumor Biology, 2017, 39, 101042831773024.	1.8	25
43	Analysis of integrated clinical trial protocols in early phases of medicinal product development. European Journal of Clinical Pharmacology, 2017, 73, 1565-1577.	1.9	14
44	RIG-I Activation Protects and Rescues from Lethal Influenza Virus Infection and Bacterial Superinfection. Molecular Therapy, 2017, 25, 2093-2103.	8.2	26
45	Funktion von extrazellulÄ r en Vesikeln und Bedeutung fļr die labormedizinische Diagnostik. Laboratoriums Medizin, 2017, 41, 299-308.	0.6	0
46	Type I interferon-mediated autoinflammation due to DNase II deficiency. Nature Communications, 2017, 8, 2176.	12.8	164
47	Abstract B44: Selective stimulation of RIG-I with a novel synthetic RNA induces strong anti-tumor immunity in mouse tumor models. , 2017, , .		7
48	Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCIâ,,¢-based Assays. Anticancer Research, 2017, 37, 353-360.	1.1	31
49	Diagnostic Performance of a Novel Multiplex Immunoassay in Colorectal Cancer. Anticancer Research, 2017, 37, 2477-2486.	1.1	16
50	G-rich DNA-induced stress response blocks type-I-IFN but not CXCL10 secretion in monocytes. Scientific Reports, 2016, 6, 38405.	3.3	4
51	Das Immunsystem der Nukleinsäreerkennung. Laboratoriums Medizin, 2016, 40, 355-366.	0.6	1
52	<scp>MDA</scp> â€5 activation by cytoplasmic doubleâ€stranded <scp>RNA</scp> impairs endothelial function and aggravates atherosclerosis. Journal of Cellular and Molecular Medicine, 2016, 20, 1696-1705.	3.6	15
53	RIG-I activation induces the release of extracellular vesicles with antitumor activity. Oncolmmunology, 2016, 5, e1219827.	4.6	44
54	Discriminating self from non-self in nucleic acid sensing. Nature Reviews Immunology, 2016, 16, 566-580.	22.7	438

GUNTHER HARTMANN

#	Article	IF	CITATIONS
55	Inflammasome-Dependent Induction of Adaptive NK Cell Memory. Immunity, 2016, 44, 1406-1421.	14.3	67
56	Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial. BMC Family Practice, 2016, 17, 49.	2.9	14
57	Cutting Edge: The RIG-I Ligand 3pRNA Potently Improves CTL Cross-Priming and Facilitates Antiviral Vaccination. Journal of Immunology, 2016, 196, 2439-2443.	0.8	42
58	lmmune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies. BMC Pharmacology & Toxicology, 2015, 16, 25.	2.4	6
59	A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1-2′O-Methylated Self RNA. Immunity, 2015, 43, 41-51.	14.3	221
60	Sequence-specific activation of the DNA sensor cGAS by Y-form DNA structures as found in primary HIV-1 cDNA. Nature Immunology, 2015, 16, 1025-1033.	14.5	202
61	Where Failure Is Not an Option –Personalized Medicine in Astronauts. PLoS ONE, 2015, 10, e0140764.	2.5	29
62	ATP hydrolysis by the viral RNA sensor RIG-I prevents unintentional recognition of self-RNA. ELife, 2015, 4, .	6.0	75
63	Selfâ€priming determines high type I <scp>IFN</scp> production by plasmacytoid dendritic cells. European Journal of Immunology, 2014, 44, 807-818.	2.9	63
64	Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA. Cell Reports, 2014, 8, 1668-1676.	6.4	87
65	AChE and RACK1 Promote the Anti-Inflammatory Properties of Fluoxetine. Journal of Molecular Neuroscience, 2014, 53, 306-315.	2.3	33
66	Efficient Solidâ€Phase Synthesis of pppRNA by Using Productâ€Specific Labeling. Angewandte Chemie - International Edition, 2014, 53, 4694-4698.	13.8	26
67	Yeast Virus-Derived Stimulator of the Innate Immune System Augments the Efficacy of Virus Vector-Based Immunotherapy. Journal of Virology, 2014, 88, 5242-5255.	3.4	12
68	Calponin-h2: a potential serum marker for the early detection of human breast cancer?. Tumor Biology, 2014, 35, 11121-11127.	1.8	8
69	Characterizing the genetic basis of innate immune response in TLR4-activated human monocytes. Nature Communications, 2014, 5, 5236.	12.8	61
70	Therapeutic Tissue Regeneration by a Macrophage Colony-Stimulating Factor Fc Conjugate. Molecular Therapy, 2014, 22, 1577-1579.	8.2	2
71	Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates. Nature, 2014, 514, 372-375.	27.8	459
72	Enzymatic Synthesis and Purification of a Defined RIG-I Ligand. Methods in Molecular Biology, 2014, 1169, 15-25.	0.9	16

#	Article	IF	CITATIONS
73	VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation. European Journal of Clinical Pharmacology, 2013, 69, 467-475.	1.9	10
74	Structure-Function Analysis of STING Activation by c[G(2′,5′)pA(3′,5′)p] and Targeting by Antiviral DN Cell, 2013, 154, 748-762.	1XAA 28.9	472
75	Turning Tumors into Vaccines: Co-opting the Innate Immune System. Immunity, 2013, 39, 27-37.	14.3	93
76	Specific expression of k63-linked ubiquitination of calmodulin-like protein 5 in breast cancer of premenopausal patients. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2125-2132.	2.5	27
77	Oxidative Damage of DNA Confers Resistance to Cytosolic Nuclease TREX1 Degradation and Potentiates STING-Dependent Immune Sensing. Immunity, 2013, 39, 482-495.	14.3	338
78	Exosomes as nucleic acid nanocarriers. Advanced Drug Delivery Reviews, 2013, 65, 331-335.	13.7	206
79	Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GM Synthase. Cell, 2013, 153, 1094-1107.	P-AMP 28.9	795
80	Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer. Cancer Research, 2013, 73, 1709-1720.	0.9	130
81	Targeting the Cytosolic Innate Immune Receptors RIG-I and MDA5 Effectively Counteracts Cancer Cell Heterogeneity in Glioblastoma. Stem Cells, 2013, 31, 1064-1074.	3.2	76
82	RIG-I Detects Triphosphorylated RNA of Listeria monocytogenes during Infection in Non-Immune Cells. PLoS ONE, 2013, 8, e62872.	2.5	68
83	A Human In Vitro Whole Blood Assay to Predict the Systemic Cytokine Response to Therapeutic Oligonucleotides Including siRNA. PLoS ONE, 2013, 8, e71057.	2.5	51
84	Endothelial RIG-I activation impairs endothelial function. Biochemical and Biophysical Research Communications, 2012, 420, 66-71.	2.1	27
85	RIG-I detects infection with live <i>Listeria</i> by sensing secreted bacterial nucleic acids. EMBO Journal, 2012, 31, 4153-4164.	7.8	153
86	Cytosolic RIG-l–like helicases act as negative regulators of sterile inflammation in the CNS. Nature Neuroscience, 2012, 15, 98-106.	14.8	60
87	Nucleic Acid Adjuvants. Advances in Immunology, 2012, 114, 1-32.	2.2	12
88	Stressing hematopoiesis and immunity: an acetylcholinesterase window into nervous and immune system interactions. Frontiers in Molecular Neuroscience, 2012, 5, 30.	2.9	32
89	A Message from the Oligonucleotide Therapeutics Society. Nucleic Acid Therapeutics, 2012, 22, 1-2.	3.6	1
90	Immunohistological analysis of inâ€transit metastasis in a patient with advanced melanoma treated with combination therapy of cytosine guanine dinucleotide oligodeoxynucleotide, dacarbazine and betaâ€interferon: A case report. Journal of Dermatology, 2012, 39, 1035-1037.	1.2	1

#	Article	IF	CITATIONS
91	Influence of Acute Exposure to High Altitude on Basal and Postprandial Plasma Levels of Gastroenteropancreatic Peptides. PLoS ONE, 2012, 7, e44445.	2.5	25
92	5′ Triphosphorylated Small Interfering RNAs Control Replication of Hepatitis B Virus and Induce an Interferon Response in Human Liver Cells and Mice. Gastroenterology, 2011, 141, 696-706.e3.	1.3	66
93	Delivery with polycations extends the immunostimulant Ribomunyl® into a potent antiviral Toll-like receptor 7/8 agonist. Antiviral Therapy, 2011, 16, 751-758.	1.0	5
94	SiRNA delivery with exosome nanoparticles. Nature Biotechnology, 2011, 29, 325-326.	17.5	299
95	Stimulation of TLR7 prior to polymicrobial sepsis improves the immune control of the inflammatory response in adult mice. Inflammation Research, 2011, 60, 271-279.	4.0	11
96	Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. European Journal of Immunology, 2011, 41, 3028-3039.	2.9	40
97	Identification of specific nuclear structural protein alterations in human breast cancer. Journal of Cellular Biochemistry, 2011, 112, 3176-3184.	2.6	6
98	Activation of Endothelial Toll-Like Receptor 3 Impairs Endothelial Function. Circulation Research, 2011, 108, 1358-1366.	4.5	107
99	Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 203-207.	2.3	55
100	<i>Listeria monocytogenes</i> is sensed by the NLRP3 and AIM2 inflammasome. European Journal of Immunology, 2010, 40, 1545-1551.	2.9	221
101	Structural and functional insights into 5′-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nature Structural and Molecular Biology, 2010, 17, 781-787.	8.2	229
102	Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 11² production. Nature Immunology, 2010, 11, 63-69.	14.5	477
103	Immunostimulatory RNA Blocks Suppression by Regulatory T Cells. Journal of Immunology, 2010, 184, 939-946.	0.8	55
104	Human Plasmacytoid Dendritic Cells Support Th17 Cell Effector Function in Response to TLR7 Ligation. Journal of Immunology, 2010, 184, 1159-1167.	0.8	96
105	Monocyte-Mediated Inhibition of TLR9-Dependent IFN-α Induction in Plasmacytoid Dendritic Cells Questions Bacterial DNA as the Active Ingredient of Bacterial Lysates. Journal of Immunology, 2010, 185, 7367-7373.	0.8	19
106	Targeted Activation of RNA Helicase Retinoic Acid–Inducible Gene-I Induces Proimmunogenic Apoptosis of Human Ovarian Cancer Cells. Cancer Research, 2010, 70, 5293-5304.	0.9	77
107	Virally Infected Mouse Liver Endothelial Cells Trigger CD8+ T-Cell Immunity. Gastroenterology, 2010, 138, 336-346.	1.3	65
	Effects of an active immunization on the immune response of laving lapanese quail (Coturnix coturnix) Ti ETOqO	0 0 rgBT	Overlock 10

108

Effects of an active immunization on the immune response of laying Japanese quail (Coturnix coturnix) Tj ETQq0 0 0 rgBT /Overlock 10 T 3.4 12 89, 1122-1128.

#	Article	IF	CITATIONS
109	Mitf silencing cooperates with IL-12 gene transfer to inhibit melanoma in mice. International Immunopharmacology, 2010, 10, 540-545.	3.8	10
110	The Chase for the RIG-I Ligand—Recent Advances. Molecular Therapy, 2010, 18, 1254-1262.	8.2	84
111	Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell and Melanoma Research, 2010, 23, 607-619.	3.3	42
112	Immunostimulatory RNA Oligonucleotides Induce an Effective Antitumoral NK Cell Response through the TLR7. Journal of Immunology, 2009, 183, 6078-6086.	0.8	42
113	Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA. Journal of Leukocyte Biology, 2009, 86, 663-670.	3.3	31
114	Complete Regression of Advanced Primary and Metastatic Mouse Melanomas following Combination Chemoimmunotherapy. Cancer Research, 2009, 69, 6265-6274.	0.9	46
115	Regulation and function of the cytosolic viral RNA sensor RIC-I in pancreatic beta cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 1768-1775.	4.1	18
116	Tumourâ€derived prostaglandin E ₂ and transforming growth factorâ€Î² synergize to inhibit plasmacytoid dendritic cellâ€derived interferonâ€Î±. Immunology, 2009, 128, 439-450.	4.4	93
117	Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature, 2009, 459, 433-436.	27.8	799
118	RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III–transcribed RNA intermediate. Nature Immunology, 2009, 10, 1065-1072.	14.5	762
119	Approaching the RNA ligand for RIGâ€I?. Immunological Reviews, 2009, 227, 66-74.	6.0	73
120	Recognition of 5′ Triphosphate by RIG-I Helicase Requires Short Blunt Double-Stranded RNA as Contained in Panhandle of Negative-Strand Virus. Immunity, 2009, 31, 25-34.	14.3	660
121	Selection of Molecular Structure and Delivery of RNA Oligonucleotides to Activate TLR7 versus TLR8 and to Induce High Amounts of IL-12p70 in Primary Human Monocytes. Journal of Immunology, 2009, 182, 6824-6833.	0.8	90
122	Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8. Journal of Allergy and Clinical Immunology, 2009, 123, 1026-1033.	2.9	66
123	TLR8-driven IL-12–dependent Reciprocal and Synergistic Activation of NK Cells and Monocytes by Immunostimulatory RNA. Journal of Immunotherapy, 2009, 32, 262-271.	2.4	30
124	Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon–independent apoptosis in human melanoma cells. Journal of Clinical Investigation, 2009, 119, 2399-411.	8.2	322
125	Gene silencing below the immune radar. Journal of Clinical Investigation, 2009, 119, 438-441.	8.2	8
126	Delivery by Cationic Gelatin Nanoparticles Strongly Increases the Immunostimulatory Effects of CpG Oligonucleotides. Pharmaceutical Research, 2008, 25, 551-562.	3.5	117

#	Article	IF	CITATIONS
127	Accessing the therapeutic potential of immunostimulatory nucleic acids. Current Opinion in Immunology, 2008, 20, 389-395.	5.5	104
128	5′-triphosphate-siRNA: turning gene silencing and Rig-l activation against melanoma. Nature Medicine, 2008, 14, 1256-1263.	30.7	353
129	TRADD Protein Is an Essential Component of the RIG-like Helicase Antiviral Pathway. Immunity, 2008, 28, 651-661.	14.3	280
130	RNA Recognition via TLR7 and TLR8. Handbook of Experimental Pharmacology, 2008, , 71-86.	1.8	77
131	RNA Interference in Scope of Immune System. , 2008, , 207-226.		Ο
132	<i>Staphylococcus aureus</i> Protein A Triggers T Cell-Independent B Cell Proliferation by Sensitizing B Cells for TLR2 Ligands. Journal of Immunology, 2007, 178, 2803-2812.	0.8	97
133	Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood, 2007, 109, 2953-2960.	1.4	54
134	A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. Cell, 2007, 129, 1401-1414.	28.9	3,390
135	siRNA and isRNA: two edges of one sword. Molecular Therapy, 2006, 14, 463-470.	8.2	214
136	5'-Triphosphate RNA Is the Ligand for RIG-I. Science, 2006, 314, 994-997.	12.6	2,094
137	Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. International Journal of Cancer, 2006, 118, 2790-2795.	5.1	39
138	Analysis of Plasmacytoid and Myeloid Dendritic Cells in Nasal Epithelium. Vaccine Journal, 2006, 13, 1278-1286.	3.1	54
139	Immunostimulatory Properties of CpG-Oligonucleotides Are Enhanced by the Use of Protamine Nanoparticles. Oligonucleotides, 2006, 16, 313-322.	2.7	38
140	T Cell-Independent, TLR-Induced IL-12p70 Production in Primary Human Monocytes. Journal of Immunology, 2006, 176, 7438-7446.	0.8	102
141	Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Medicine, 2005, 11, 263-270.	30.7	1,153
142	Preferential expression and function of Toll-like receptor 3 in human astrocytes. Journal of Neuroimmunology, 2005, 159, 12-19.	2.3	234
143	CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. European Journal of Immunology, 2005, 35, 2347-2357.	2.9	71
144	No Indication for a Defect in Toll-Like Receptor Signaling in Patients with Hyper-IgE Syndrome. Journal of Clinical Immunology, 2005, 25, 321-328.	3.8	16

#	Article	IF	CITATIONS
145	Spontaneous Formation of Nucleic Acid-based Nanoparticles Is Responsible for High Interferon-α Induction by CpG-A in Plasmacytoid Dendritic Cells. Journal of Biological Chemistry, 2005, 280, 8086-8093.	3.4	160
146	B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides. Clinical Cancer Research, 2005, 11, 1490-1499.	7.0	118
147	Plasmacytoid Dendritic Cells Control TLR7 Sensitivity of Naive B Cells via Type I IFN. Journal of Immunology, 2005, 174, 4043-4050.	0.8	319
148	Inhibition of Toll-Like Receptor 7- and 9-Mediated Alpha/Beta Interferon Production in Human Plasmacytoid Dendritic Cells by Respiratory Syncytial Virus and Measles Virus. Journal of Virology, 2005, 79, 5507-5515.	3.4	208
149	CpG oligonucleotides induce strong humoral but only weak CD4+ T cell responses to protein antigens in rhesus macaques in vivo. Vaccine, 2005, 23, 3310-3317.	3.8	20
150	Replication-Dependent Potent IFN-α Induction in Human Plasmacytoid Dendritic Cells by a Single-Stranded RNA Virus. Journal of Immunology, 2004, 173, 5935-5943.	0.8	191
151	IL-12p70-Dependent Th1 Induction by Human B Cells Requires Combined Activation with CD40 Ligand and CpG DNA. Journal of Immunology, 2004, 172, 954-963.	0.8	147
152	CpG-A and CpG-B oligonucleotides differentially enhance human peptide–specific primary and memory CD8+ T-cell responses in vitro. Blood, 2004, 103, 2162-2169.	1.4	94
153	CpG Oligonucleotides Elicit Antitumor Responses in a Human Melanoma NOD/SCID Xenotransplantation Model. Journal of Investigative Dermatology, 2004, 122, 387-391.	0.7	18
154	Structural studies of oligonucleotides containing G-quadruplex motifs using AFM. Biochemical and Biophysical Research Communications, 2004, 313, 1065-1072.	2.1	44
155	Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood, 2004, 103, 1391-1397.	1.4	164
156	Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood, 2004, 103, 3058-3064.	1.4	264
157	Technology evaluation: BAY-50-4798, Bayer. Current Opinion in Molecular Therapeutics, 2004, 6, 221-7.	2.8	0
158	Activation of Dendritic Cells and Induction of T Cell Responses by Hpv 16 L1/E7 Chimeric Virus-Like Particles are Enhanced by Cpg ODN or Sorbitol. Antiviral Therapy, 2004, 9, 479-489.	1.0	18
159	Rational design of new CpG oligonucleotides that combine B cell activation with high IFNâ€î± induction in plasmacytoid dendritic cells. European Journal of Immunology, 2003, 33, 1633-1641.	2.9	276
160	Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells. Journal of Immunology, 2003, 170, 4465-4474.	0.8	305
161	CpG-A Oligonucleotides Induce a Monocyte-Derived Dendritic Cell-Like Phenotype That Preferentially Activates CD8 T Cells. Journal of Immunology, 2003, 170, 3468-3477.	0.8	67
162	CpG: unraveling the key to B-cell function. Blood, 2003, 101, 4230-4231.	1.4	2

GUNTHER HARTMANN

#	Article	IF	CITATIONS
163	Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Research, 2003, 63, 6478-87.	0.9	249
164	CpG oligonucleotides: novel regulators of osteoclast differentiation. FASEB Journal, 2002, 16, 274-282.	0.5	56
165	Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model. Journal of Immunology, 2002, 169, 3892-3899.	0.8	178
166	Plasmacytoid dendritic cells: the key to CpG. Human Immunology, 2002, 63, 1111-1119.	2.4	135
167	Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. Journal of Immunology, 2002, 168, 4531-4537.	0.8	1,780
168	Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. European Journal of Immunology, 2002, 32, 3235-3245.	2.9	107
169	Plasmacytoid Dendritic Cells: A New Cutaneous Dendritic Cell Subset with Distinct Role in Inflammatory Skin Diseases. Journal of Investigative Dermatology, 2002, 119, 1096-1102.	0.7	384
170	Antisense therapy in oncology: new hope for an old idea?. Lancet, The, 2001, 358, 489-497.	13.7	223
171	Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-Î ³ and TNF-α production. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 281, R1264-R1273.	1.8	263
172	Shock waves: a novel method for cytoplasmic delivery of antisense oligonucleotides. Journal of Molecular Medicine, 2001, 79, 306-313.	3.9	30
173	Toll-like receptor expression reveals CpC DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. European Journal of Immunology, 2001, 31, 3026-3037.	2.9	704
174	Identification of CpG oligonucleotide sequences with high induction of IFN- $\hat{I} \pm / \hat{I}^2$ in plasmacytoid dendritic cells. European Journal of Immunology, 2001, 31, 2154-2163.	2.9	790
175	Distinct CpG oligonucleotide sequences activate human γ δT cells via interferon-α/-β. European Journal of Immunology, 2001, 31, 3525-3534.	2.9	68
176	Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. , 2001, 31, 3026.		3
177	Identification of CpG oligonucleotide sequences with high induction of IFN- $\hat{l} \pm / \hat{l}^2$ in plasmacytoid dendritic cells. , 2001, 31, 2154.		3
178	Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo. Journal of Immunology, 2000, 164, 1617-1624.	0.8	550
179	Enhanced Dendritic Cell Maturation by TNF-α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo. Journal of Immunology, 2000, 165, 6278-6286.	0.8	167
180	HIGH ALTITUDE INCREASES CIRCULATING INTERLEUKIN-6, INTERLEUKIN-1 RECEPTOR ANTAGONIST AND C-REACTIVE PROTEIN. Cytokine, 2000, 12, 246-252.	3.2	376

#	Article	IF	CITATIONS
181	Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells. Journal of Immunology, 2000, 164, 944-953.	0.8	567
182	CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9305-9310.	7.1	569
183	CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Therapy, 1999, 6, 893-903.	4.5	191
184	Mechanisms and therapeutic applications of immune stimulatory CpG DNA. , 1999, 84, 113-120.		70
185	How to Characterize and Improve Oligonucleotide Uptake into Leukocytes. Perspectives in Antisense Science, 1999, , 41-56.	0.2	0
186	The hairy cell leukemia cell line Eskol spontaneously synthesizes tumor necrosis factor-α and nitric oxide. Leukemia Research, 1998, 22, 501-507.	0.8	8
187	Adrenaline enhances LPS-induced IL-10 synthesis: evidence for protein kinase A-mediated pathway. International Journal of Immunopharmacology, 1998, 20, 57-69.	1.1	40
188	Raised leptin concentrations at high altitude associated with loss of appetite. Lancet, The, 1998, 352, 1119-1120.	13.7	131
189	The specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. Gastroenterology, 1998, 114, A932.	1.3	1
190	Oligonucleotide uptake in leukocytes is dependent on extracellular calcium: a hint for the involvement of adhesion molecules?. Nucleosides & Nucleotides, 1998, 17, 1767-1773.	0.5	3
191	In Vivo Synthesis of Tumor Necrosis Factorâ€Î± in Healthy Humans after Live Yellow Fever Vaccination. Journal of Infectious Diseases, 1998, 177, 774-778.	4.0	58
192	Adrenomedullin: A Player at High Altitude?. Chest, 1998, 113, 1428.	0.8	15
193	Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. Journal of Leukocyte Biology, 1998, 63, 101-107.	3.3	167
194	Plasma Adrenomedullin Levels, Body Fluid Status, and End-Stage Renal Failure. Nephron, 1998, 80, 232-233.	1.8	9
195	Antisense Strategies for Inhibition of Tumor Necrosis Factor-α Synthesis. Nucleosides & Nucleotides, 1997, 16, 629-634.	0.5	0
196	Suppression of tumor necrosis factor-α production by interleukin-10 is enhanced by cAMP-elevating agents. European Journal of Pharmacology, 1997, 321, 231-239.	3.5	32
197	Oligonucleotides: Extrapolating from in vitro to in vivo. Nature Medicine, 1997, 3, 702-702.	30.7	3
198	Taming TNF: strategies to restrain this proinflammatory cytokine. Trends in Immunology, 1997, 18, 487-492.	7.5	255

#	Article	IF	CITATIONS
199	Oligodeoxynucleotides Enhance Lipopolysaccharide-Stimulated Synthesis of Tumor Necrosis Factor: Dependence on Phosphorothioate Modification and Reversal by Heparin. Molecular Medicine, 1996, 2, 429-438.	4.4	81
200	Specific Suppression of Human Tumor Necrosis Factor-α Synthesis by Antisense Oligodeoxynucleotides. Oligonucleotides, 1996, 6, 291-299.	4.3	33